Freestone Grove Partners’s Neurocrine Biosciences NBIX Stock Holding History

Freestone Grove Partners’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.58M	Sell	11,997 -128,532	-91%	-$17.1M	0.01%	401
2025 Q4	$19.9M	Buy	140,529 +8,191	+6%	+$1.19M	0.14%	210
2025 Q3	$18.6M	Sell	132,338 -35,795	-21%	-$4.85M	0.14%	224
2025 Q2	$21.1M	Buy	168,133 +162,924	+3,128%	+$18.7M	0.16%	193
2025 Q1	$576K	Buy	+5,209	New	+$660K	0.01%	395

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Freestone Grove Partners's NBIX Position: Q1 2026 in Review

Freestone Grove Partners reduced its Neurocrine Biosciences (NBIX) stake by 91% in Q1 2026, selling an estimated $17.1M and leaving 11,997 shares worth $1.58M. The position accounts for 0.01% of the portfolio, ranked #401.

Freestone Grove Partners first reported a position in NBIX in Q1 2025 and has held it in 5 quarters since. The position peaked at $21.1M in Q2 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Freestone Grove Partners held 11,997 shares of Neurocrine Biosciences worth $1.58M as of Q1 2026.
Freestone Grove Partners sold 128,532 Neurocrine Biosciences shares in Q1 2026, an estimated $17.1M.
Neurocrine Biosciences made up 0.01% of Freestone Grove Partners's portfolio in Q1 2026, its #401 holding.
Freestone Grove Partners first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 5 quarters since.
Freestone Grove Partners's Neurocrine Biosciences position peaked at $21.1M in Q2 2025.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.